Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors – Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
This was the stock's second consecutive day of losses.
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Yahoo Finance2d
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors.
Yahoo Finance7d
Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call
Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...
ETF Daily News7d
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $862.00 at Leerink Partners
Shares of NASDAQ:REGN opened at $716.72 on Tuesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a fifty-two ...
ETF Daily News5d
Leerink Partners Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Outperform
Regeneron Pharmaceuticals has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
The stock's fall snapped a three-day winning streak.